A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
-
- STATUS
- Not Recruiting
-
- participants needed
- 16
-
- sponsor
- Neurocrine Biosciences
Updated on 22 July 2024
Summary
This is a phase 1, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of opicapone when administered orally once daily for 14 days as adjunctive therapy to carbidopa/levodopa in subjects with Parkinson's disease.
Details
| Condition | Parkinson Disease |
|---|---|
| Age | 18years - 85years |
| Treatment | Opicapone, Carbidopa Levodopa |
| Clinical Study Identifier | NCT03496870 |
| Sponsor | Neurocrine Biosciences |
| Last Modified on | 22 July 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.